Khalid, S.
Calderon-Larranaga, S.
Sami, A.
Hawley, S.
Judge, A.
Arden, N.
Van Staa, T. P.
Cooper, C.
Abrahamsen, B.
Javaid, M. Kassim
Prieto-Alhambra, D.
Funding for this research was provided by:
National Osteoporosis Society
National Institute for Health Research Clinician Scientist award (CS-2013-13-012)
NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol
Article History
Received: 1 March 2021
Accepted: 3 December 2021
First Online: 9 February 2022
Declarations
:
: This study has been approved by the Independent Scientific Advisory Committee (ISAC, protocol number 14_110). Ethics approval was not required.
: Not applicable.
: The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display, and store the contribution; (ii) translate the contribution into other languages, create adaptations and reprints, and include within collections and create summaries, extracts, and/or abstracts of the contribution; (iii) create any other derivative work(s) based on the contribution; (iv) exploit all subsidiary rights in the contribution; (v) the inclusion of electronic links from the contribution to third party material wherever it may be located; and (vi) licence any third party to do any or all of the above.
: The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.
: The study funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors had full access to all of the data in the study and take responsibility for the integrity of such data and the accuracy of the data analysis.
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare Cyrus Cooper reports Personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. Kassim Javaid reports honoraria, unrestricted research grants, and travel and/or subsistence expenses from Amgen, Lilly UK, Shire, Internis, Consilient Health, Stirling Anglia Pharmaceuticals, Mereo Biopharma, Optasia Medical, Zebra Medical Vision, Kyowa Kirin Hakin, and UCB. Andrew Judge reports consultancy fees, lecture fees, and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, and Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, Inc., and received consortium research grants from Roche. Bo Abrahamsen reports Institutional research grants UCB and Novartis. Advisory board and consulting fees UCB. Daniel Prieto Alhambra reports DPA’s institution received speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier; and financial support to organise educational activities from Janssen (on behalf of IMI-funded EHDEN and EMIF consortiums) and Synapse Management Partners. Sara Khalid, Sara Calderon-Larranaga, Arvind Sami, Samuel Hawley, and Tjeerd P Van Staa declare that they have no conflict of interest.